PDF(Pubmed)
Abstract：
UNASSIGNED: Pharmacists\' knowledge of the differences in the characteristics between generic drugs and biosimilars is essential to ensure good practice and lower pharmaceutical bills.
UNASSIGNED: This study aimed to evaluate community pharmacists\' knowledge and perception of using and substituting biosimilars and generic drugs.
UNASSIGNED: A pilot cross-sectional study was performed over 2 months (August-September 2022) targeting community pharmacists in their work site.
UNASSIGNED: Data were collected using a uniform survey given to 75 pharmacists. Afterward, a knowledge score was generated by summing several individual scores of statements regarding generic drugs and biosimilars.
UNASSIGNED: Overall, pharmacists had moderate to low knowledge scores, namely, with the statements tackling biosimilars. No significance was reported between these scores and their general characteristics. As regards their substitution, most pharmacists agreed to substitute generic drugs if the brand was not available, while the doctor\'s approval was crucial for biosimilar switching. Most participants perceived equal effectiveness of generic drugs but similar to a lower one for biosimilars compared to the reference medication. Pharmacists highlighted the need to include generic drugs and biosimilars in the continuing education program and workshops.
UNASSIGNED: To promote their use, improving pharmacists\' knowledge can help overcome misconceptions about generic drugs and biosimilars. It is recommended that health care stakeholders focus on fostering good understanding among pharmacists to enhance access to medication.
UNASSIGNED: This study aimed to evaluate community pharmacists\' knowledge and perception of using and substituting biosimilars and generic drugs.
UNASSIGNED: A pilot cross-sectional study was performed over 2 months (August-September 2022) targeting community pharmacists in their work site.
UNASSIGNED: Data were collected using a uniform survey given to 75 pharmacists. Afterward, a knowledge score was generated by summing several individual scores of statements regarding generic drugs and biosimilars.
UNASSIGNED: Overall, pharmacists had moderate to low knowledge scores, namely, with the statements tackling biosimilars. No significance was reported between these scores and their general characteristics. As regards their substitution, most pharmacists agreed to substitute generic drugs if the brand was not available, while the doctor\'s approval was crucial for biosimilar switching. Most participants perceived equal effectiveness of generic drugs but similar to a lower one for biosimilars compared to the reference medication. Pharmacists highlighted the need to include generic drugs and biosimilars in the continuing education program and workshops.
UNASSIGNED: To promote their use, improving pharmacists\' knowledge can help overcome misconceptions about generic drugs and biosimilars. It is recommended that health care stakeholders focus on fostering good understanding among pharmacists to enhance access to medication.
摘要：
■药剂师\'了解仿制药和生物仿制药之间的特性差异对于确保良好的实践和降低药品费用至关重要。
■本研究旨在评估社区药剂师对使用和替代生物仿制药和仿制药的知识和看法。
■针对工作场所的社区药剂师进行了为期2个月（2022年8月至9月）的试点横断面研究。
■使用对75名药剂师的统一调查收集数据。之后,通过对有关仿制药和生物仿制药的几个单独的评分进行求和,得出知识评分.
■总的来说，药剂师的知识得分中等到较低，即,关于生物仿制药的声明。在这些分数和它们的一般特征之间没有报告显著性。至于他们的替代，如果该品牌不可用，大多数药剂师同意替代仿制药，而医生的批准对于生物仿制药的转换至关重要。大多数参与者认为仿制药的有效性相同，但与参考药物相比，生物仿制药的有效性较低。药剂师强调需要将仿制药和生物仿制药纳入继续教育计划和研讨会。
■为了推广它们的使用，提高药剂师的知识可以帮助克服对仿制药和生物仿制药的误解。建议医疗保健利益相关者专注于促进药剂师之间的良好理解，以增加获得药物的机会。
■本研究旨在评估社区药剂师对使用和替代生物仿制药和仿制药的知识和看法。
■针对工作场所的社区药剂师进行了为期2个月（2022年8月至9月）的试点横断面研究。
■使用对75名药剂师的统一调查收集数据。之后,通过对有关仿制药和生物仿制药的几个单独的评分进行求和,得出知识评分.
■总的来说，药剂师的知识得分中等到较低，即,关于生物仿制药的声明。在这些分数和它们的一般特征之间没有报告显著性。至于他们的替代，如果该品牌不可用，大多数药剂师同意替代仿制药，而医生的批准对于生物仿制药的转换至关重要。大多数参与者认为仿制药的有效性相同，但与参考药物相比，生物仿制药的有效性较低。药剂师强调需要将仿制药和生物仿制药纳入继续教育计划和研讨会。
■为了推广它们的使用，提高药剂师的知识可以帮助克服对仿制药和生物仿制药的误解。建议医疗保健利益相关者专注于促进药剂师之间的良好理解，以增加获得药物的机会。
